Long-term Safety Study of Chronocort in the Treatment of Participants with Congenital Adrenal Hyperplasia

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Congenital Adrenal Hyperplasia
Interventions
DRUG

Chronocort

Hydrocortisone modified-release capsule 5 mg and 10 mg

Trial Locations (21)

14033

Diurnal Investigational Site in Caen, Caen

31059

Diurnal Investigational Site in Toulouse (Children's hospital), Toulouse

Diurnal Investigational Site in Toulouse, Toulouse

32207

Diurnal Investigational Site in Florida, Jacksonville

33604

Diurnal Investigational Site in Pessac, Pessac

48114

Diurnal Investigational Site in Michigan, Ann Arbor

52242

Diurnal Investigational Site in Iowa, Iowa City

53226

Diurnal Investigational Site in Wisconsin, Milwaukee

55901

Diurnal Investigational Site in Minnesota, Rochester

69677

Diurnal investigational Site in Lyon, Lyon

75235

Diurnal Investigational Site in Texas, Dallas

75651

Diurnal Investigational Site in Paris, Paris

89148

Diurnal Investigational Site in Nevada, Las Vegas

90027

Diurnal Investigational Site in California, Los Angeles

92868

Diurnal Investigational Site in California, Orange

98105

Diurnal Investigational Site in Washington, Seattle

20892-1932

National Institutes of Health Center, Bethesda

241-0811

Diurnal Investigational Site in Asahi-ku, Yokohama

113-8519

Diurnal Investigational Site in Yushima, Bunkyō-Ku

157-8535

Diurnal Investigational Site in Okura, Setagaya-Ku

162-8655

Diurnal Investigational Site in Toyama, Shinjuku-Ku

All Listed Sponsors
lead

Neurocrine UK Limited

INDUSTRY